Blue Horseshoe Stocks: JNUG Recap & Much More

Direxion Daily Jr Gld Mnrs Bull 3X ETF  (JNUG) – Recap

Despite only providing a fleeting opportunity for gains on Tuesday morning after we submitted our options trading idea for the JNUG chain, we followed up with a reminder in yesterday’s report that the idea was still in play, and that we’d need to keep our heads on a swivel looking out for the move we were hoping for.

With the help of a Fed rate hike of a quarter of a percentage point, announced by Chairperson Janet Yellen yesterday, our specified contracts, the JNUG 03/31 $7-8 Calls took a serious turn for the better.

The daily ranges and potential profits were as follows:

$7 Calls – Range: .40-1.40 – Max Gain: 250%
$7.50 Calls – Range: .35-1.00 – Max Gain: 186%
$8 Calls – Range: .20-.87 – Max Gain: 335%

Once again, we’re going to reiterate our interest in these ideas, which could be in line to extend their highs, with JNUG gapping up in early trading this morning.


Aralez Pharmaceuticals, Inc. ARLZ

We placed ARLZ on bottom watch yesterday morning in what turned out to be a fantastic stroke of good timing. We just wanted to update readers this morning on the reversal which did indeed occur during the session. While the intraday gain potential topped out at 25% as the stock ran from the open (and also low of day) at 2.11 to as much as 2.63.

The inverted hammer candle that the stock posted yesterday is often thought to be an indicator of the end of a downward pattern, so we’ll be very interested to continue tracking ARLZ in sessions to come. Chart indicators are still looking very ripe, and we’d be surprised if the show was over after just a 25% rise.


Cannabis Sector Comments

Lastly, we just want to address the cannabis sector, particularly those stocks that are connected to legal recreational marijuana. After some very damaging comments made recently by the Trump Administration wherein it was suggested that the government could crack down on legal weed, yesterday we witnessed something of a reversal from Jeff Sessions.

Sessions appeared to hint at insufficient DOJ funding as a primary reason that perhaps the current regime will not be changing Obama-era guidance on leaving the treatment of recreational weed as a states’ rights issue.

On the heels of this development, we’re going to want to keep closer tabs on the cannabis sector once again, particularly those plays that lost a lot of ground after the first round of comments from Washington.

Some of our go-to favorites in the space have been OWCP, TRTC, SING, SGDH, CBIS, and MJNA, so we’ll be tracking these more closely in the days and weeks ahead, along with the sector as a whole, as stated above.


Fresh Options Idea:

The TSLA chart is looking ripe for a recovery, and the stock is gapping up moderately in premarket trading this morning. We want to signal a range of calls to monitor in the TSLA chain to potentially take advantage of what could be a protracted recovery. We’re going to zero in on the TSLA 04/07 $270-277.50 Calls, and monitor them in the days and weeks ahead.


Extended Watchlist:
NAK, ZSAN, ORCL, TPLM, PLX, RXII, IDRA

Blue Horseshoe Stocks: WFM Followup, ZSAN & More

Whole Foods Market, Inc. WFM – Options Update

Our primary focus for yesterday morning’s premarket report was our running options idea from last week. We were mentioning that the WFM 02/17 $30 and 30.50 Calls had begun to heat up, and we didn’t want to miss out on the activity that seemed ready to kick our idea into effect.

Our assumptions turned out to be accurate, with WFM stringing on another good session performance. The $30 Calls traded up from a low of .54 to .90 (+66%), while the $30.50’s made their way from .20-.42 (+110%).

We also mentioned that a break of the 50DMA at 30.76 for WFM would prompt us to look at contracts with a higher strike price and later expiration, the WFM 02/24 $31 Calls. We did indeed witness a breach of that price point toward the end of the session, and those calls came into play as well, running from 20-.35 for a chance at a nice 75% gain.

Should the solid uptrend WFM has been putting together continue into future sessions, these could be an ongoing item of interest for us.


Zosano Pharma Corp. ZSAN

ZSAN is a play we highlighted on Monday after the company reported that in its ZOTRIP pivotal efficacy study, its M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints.

We mentioned that not only were we going to experience the effect of positive study data, but a technically ripening chart as well, leading us to put the stock on high alert in coming sessions.

It was a good decision, as the stock has really gained momentum this week, putting together some solid sessions. In fact, yesterday the stock closed as the NASDAQ’s top gainer of the day. We’ve watched as ZSAN has traded up from a low of 1.65 to yesterday’s new high of 3.49, representing an intraweek upswing of 112% Cheers to those of our readers who came along for the ride!



Opko Health, Inc. OPK

We put OPK on bottom watch earlier this month, and after a few sessions of further consolidation, the past four trading days have shown some convincing bottom-bounce action.

The stock ultimately found support at the 7.99-level last week, from which it has logged five straight sessions of higher highs and higher lows, reaching 8.66 yesterday. While that action only equates to an 8% increase, it’s the massive gap on the chart to the upside from just under $10 to just over $11.50. We’ll look for the stock to continue to build gradually and maintain the current trend in hopes of seeing a run toward a gap-fill.


FRESH OPTIONS IDEA:

Kate Spade & Co. KATE Weekly $20 and $21 Calls


Extended Watchlist:
RSII, MAXD, SRMX, CLSN, TPX

Blue Horseshoe Stocks: News Plays & Special Reminder

Aeterna Zentaris, Inc. AEZS

AEZS is gapping up this morning on the heels of some news. It’s been quite a few months since we last mentioned this stock. That was back in the fall, and we subsequently witnessed quite a surge from the stock after that.

Since then, so far in 2017 the stock has come down to record new annual lows, and recently has been making incremental increases off of that bottom. In light of today’s news, described below, we think it’s a good time to put AEZS back on a more intensive watch.

The company announced this morning, following a comprehensive review Phase 3 clinical data on Macrilen™ for the evaluation of growth hormone deficiency, that Macrilen™ demonstrated performance supportive of achieving registration with the FDA. The FDA has agreed to consider the Company’s conclusions during a Type A meeting, which is currently being scheduled. (>>View PR)


Zosano Pharma Corp. ZSAN

Speaking of fresh news plays, we also want to highlight the announcement coming from ZSAN this morning that presently has the stock gapping up in the premarket to the tune of 50%

This morning ZSAN reported that in its ZOTRIP pivotal efficacy study, the company’s M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints. It certainly explains the premarket hoopla, and warrants our observation as we kick off a new trading week.

The chart also has some attractive features which we’ve pointed out on the snapshot below:


**SPECIAL REMINDER**

To wrap things up this morning, we want to leave our readers with a quick heads up on a big Tuesday coming up. We’ve got a special report coming out tomorrow prior to the opening bell. It could represent quite an opportunity, so tomorrow is definitely not the day to miss out on our premarket report!

Be sure to stay locked onto your email inboxes or BlueHorseshoeStocks.com tomorrow between 9:00 to 9:15AM, and lean on those refresh buttons!


Extended Watchlist:
MCIG, MYHI, ADVT, MJTK, QSIM, NK